3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
25
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Myelodysplastic Syndromes
16
Hodgkin Disease
13
Lymphoma, Non-Hodgkin
11
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma
8
Leukemia, Biphenotypic, Acute
8
Leukemia
8
Burkitt Lymphoma
7
Breast Neoplasms
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neuroblastoma
5
Neoplasms
5
Multiple Myeloma
5
Lymphoma, Mantle-Cell
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Hematologic Neoplasms
5
Triple Negative Breast Neoplasms
4
Sarcoma
4
Rhabdomyosarcoma
4
Medulloblastoma
4
Lymphoma, Follicular
4
Anemia, Refractory, with Excess of Blasts
4
Leukemia, Myelomonocytic, Chronic
3
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Myeloproliferative Disorders
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Interventions
Specimen Handling
1
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Filgrastim
×
1 year
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled